07:00 , Oct 31, 2011 |  BioCentury  |  Regulation

Lessons from PSA debate

While the medical community debates a U.S. task force's recommendation against PSA screening for prostate cancer, the implications are far broader: The task force's methodology for subjectively balancing benefit and harm is being applied to...